In large part, owning or eschewing Teva boils down to your opinion about what will become of Copaxone in the US market. I happen to think the FDA will approve a generic version of Copaxone in the next few years, which will make it all but impossible for Teva to meet its 2015 sales and EPS guidance.
This may not matter much if you’re in Teva for a swing trade, but it matters a lot if you’re considering it as a long-term investment.
News 
Market Data 
Discover 
